|
?:abstract
|
-
Proposing a theory about the pathophysiology of cytokine storm in COVID19, we were to find the potential drugs to treat this disease and to find any effect of these drugs on the virus infectivity through an in silico study COVID-19-induced ARDS is linked to a cytokine storm phenomenon not explainable solely by the virus infectivity Knowing that ACE2, the hydrolyzing enzyme of AngII and SARS-CoV2 receptor, downregulates when the virus enters the host cells, we hypothesize that hyperacute AngII upregulation is the eliciting factor of this ARDS We were to validate this theory through reviewing previous studies to figure out the role of overzealous activation of AT1R in ARDS According to this theory losartan may attenuate ARDS in this disease Imatinib, has previously been elucidated to be promising in modulating lung inflammatory reactions and virus infectivity in SARS and MERS We did an in silico study to uncover any probable other unconsidered inhibitory effects of losartan and imatinib against SARS-CoV2 pathogenesis Reviewing the literature, we could find that over-activation of AT1R could explain precisely the mechanism of cytokine storm in COVID19 Our in silico study revealed that losartan and imatinib could probably: (1) decline SARS-CoV2 affinity to ACE2 (2) inhibit the main protease and furin, (3) disturb papain-like protease and p38MAPK functions Our reviewing on renin-angiotensin system showed that overzealous activation of AT1R by hyper-acute excess of AngII due to acute downregulation of ACE2 by SARS-CoV2 explains precisely the mechanism of cytokine storm in COVID-19 Besides, based on our in silico study we concluded that losartan and imatinib are promising in COVID19 [ABSTRACT FROM AUTHOR] Copyright of In Silico Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder\'s express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}